A Novel RNA Methylation-Related Prognostic Signature and Its Tumor Microenvironment Characterization in Hepatocellular Carcinoma

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2024 Aug 19

PMID 39155614

Authors

Luzheng Liu

Jiacheng Chen

Fei Ye

Yanggang Yan

Yong Wang

Jincai Wu

Affiliations

Soon will be listed here.

Abstract

Introduction: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system. RNA methylation plays an important role in tumorigenesis and metastasis, which could alter gene expression and even function at multiple levels, such as RNA splicing, stability, translocation, and translation. In this study, we aimed to conduct a comprehensive analysis of RNA methylation-related genes (RMGs) in HCC and their relationship with survival and clinical features.

Methods: A retrospective analysis was performed using publicly available HCC-related datasets. The differentially expressed genes (DEGs) between HCC and controls were identified from TCGA-LlHC and intersected with RMGs to obtain differentially expressed RNA methylation-related genes (DERMGs). Regression analysis was used to screen for prognostic genes and construct risk models. Simultaneously, clinical, immune infiltration and therapeutic efficacy analyses were performed. Finally, multivariate cox regression was used to identify independent risk factors, and quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate the expression levels of the core genes of the model.

Results: A 21-gene risk model for HCC was established with excellent performance based on ROC curves and survival analysis. Risk scores correlated with tumor grade, pathologic T, and TNM stage. Immune infiltration analysis showed correlations with immune scores, 11 immune cells, and 30 immune checkpoints. Low-risk patients showed a higher susceptibility to immunotherapy. The risk score and TNM stage were independent prognostic factors. qRT-PCR confirmed higher expression of PRDM9, ALPP, and GAD1 in HCC.

Conclusions: This study identified RNA methylation-related signature genes in HCC and constructed a risk model that predicts patient outcomes and reflects the immune microenvironment. Prognostic genes are involved in complex regulatory mechanisms, which may be useful for cancer diagnosis, prognosis, and therapy.

References

Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G . MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 2021; 12(7):691. PMC: 8270967. DOI: 10.1038/s41419-021-03973-5. View

Caux C, Ramos R, Prendergast G, Bendriss-Vermare N, Menetrier-Caux C . A Milestone Review on How Macrophages Affect Tumor Growth. Cancer Res. 2017; 76(22):6439-6442. DOI: 10.1158/0008-5472.CAN-16-2631. View

Geeleher P, Cox N, Huang R . pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014; 9(9):e107468. PMC: 4167990. DOI: 10.1371/journal.pone.0107468. View

Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z . N-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021; 12(1):6314. PMC: 8563902. DOI: 10.1038/s41467-021-26718-6. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Wu R, Wang C, Li Z, Xiao J, Li C, Wang X . SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. J Immunother Cancer. 2020; 8(2). PMC: 7651737. DOI: 10.1136/jitc-2020-001037. View

Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoel M . Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial. Clin Transl Gastroenterol. 2022; 13(6):e00492. PMC: 9236598. DOI: 10.14309/ctg.0000000000000492. View

Jin Y, Liang Z, Zhou W, Zhou L . Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms. Hepatol Int. 2019; 13(2):180-189. DOI: 10.1007/s12072-018-9920-8. View

Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K . YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020; 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. View

10.

Zhang J, Gao J, Hu M, Xu S, Cheng C, Zheng W . Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma. Eur J Med Res. 2023; 28(1):46. PMC: 9881284. DOI: 10.1186/s40001-023-01016-7. View

11.

Ma H, Yamamoto G, Xu J, Liu X, Karin D, Kim J . IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol. 2020; 72(5):946-959. PMC: 7167339. DOI: 10.1016/j.jhep.2019.12.016. View

12.

Sun C, Sun L, Li Y, Kang X, Zhang S, Liu Y . Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol. 2013; 30(2):503. DOI: 10.1007/s12032-013-0503-1. View

13.

Liu T, Li R, Huo C, Li J, Yao J, Ji X . Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis. Front Cell Dev Biol. 2021; 9:682002. PMC: 8366777. DOI: 10.3389/fcell.2021.682002. View

14.

Wang X, Liu Y, Han A, Tang C, Xu R, Feng L . The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability. Oncogene. 2022; 41(47):5107-5120. DOI: 10.1038/s41388-022-02477-6. View

15.

Zhu J, Huang S, Wu G, Huang C, Li X, Chen Z . Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma. Dig Dis Sci. 2015; 60(10):3019-31. DOI: 10.1007/s10620-015-3734-5. View

16.

Peng F, Xu J, Cui B, Liang Q, Zeng S, He B . Oncogenic AURKA-enhanced N-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Res. 2020; 31(3):345-361. PMC: 8027457. DOI: 10.1038/s41422-020-00397-2. View

17.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

18.

Sun S, Zhou W, Li X, Peng F, Yan M, Zhan Y . Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer. Cancer Commun (Lond). 2021; 41(9):851-866. PMC: 8441052. DOI: 10.1002/cac2.12190. View

19.

Zhang B, Zhou J . CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis. Bioengineered. 2022; 13(4):9049-9062. PMC: 9161912. DOI: 10.1080/21655979.2022.2057761. View

20.

Huang P, Qiu J, Li B, Hong J, Lu C, Wang L . Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem. 2011; 44(8-9):582-9. DOI: 10.1016/j.clinbiochem.2011.02.012. View